Tropical spastic paraparesis: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|A disease caused by the human T-lymphotropic virus 1}} | |||
{{Use dmy dates|date=October 2023}} | |||
'''Tropical spastic paraparesis''' (TSP), also known as '''HTLV-1 associated myelopathy''' (HAM), is a progressive [[neurological disorder]] caused by the [[human T-lymphotropic virus 1]] (HTLV-1). It primarily affects the [[spinal cord]], leading to muscle weakness, spasticity, and other neurological symptoms. | |||
TSP is caused by the [[ | |||
== | ==Signs and symptoms== | ||
Tropical spastic paraparesis is characterized by progressive weakness and stiffness of the legs, leading to difficulty walking. Patients may also experience [[back pain]], [[urinary incontinence]], and [[erectile dysfunction]]. Sensory disturbances, such as numbness or tingling, can occur, although they are less common. | |||
==Causes== | |||
TSP is caused by infection with the [[human T-lymphotropic virus 1]] (HTLV-1), a [[retrovirus]] that primarily infects [[T cells]]. The virus is transmitted through [[blood]], [[sexual contact]], and from mother to child via [[breastfeeding]]. Not all individuals infected with HTLV-1 develop TSP; the disease occurs in a small percentage of those infected. | |||
==Pathophysiology== | |||
The exact mechanism by which HTLV-1 causes TSP is not fully understood. It is believed that the virus triggers an [[immune response]] that leads to inflammation and damage to the [[spinal cord]]. This results in the characteristic symptoms of the disease. | |||
==Diagnosis== | ==Diagnosis== | ||
Diagnosis of TSP involves clinical evaluation, [[magnetic resonance imaging]] (MRI) of the spinal cord, and laboratory tests to detect HTLV-1 antibodies in the blood or [[cerebrospinal fluid]]. | |||
==Treatment== | ==Treatment== | ||
There is no cure for TSP, | There is no cure for TSP, and treatment focuses on managing symptoms. [[Corticosteroids]] and other immunosuppressive drugs may be used to reduce inflammation. [[Physical therapy]] can help maintain mobility and muscle strength. | ||
==Prognosis== | |||
The progression of TSP varies among individuals. Some patients experience a slow progression of symptoms, while others may have a more rapid decline. Early diagnosis and management can help improve quality of life. | |||
==Epidemiology== | ==Epidemiology== | ||
TSP is most | TSP is most commonly found in regions where HTLV-1 is endemic, such as parts of [[Japan]], the [[Caribbean]], [[South America]], and [[Africa]]. The prevalence of the disease is higher in women than in men. | ||
== | ==Related pages== | ||
* [[Human T-lymphotropic virus | * [[Human T-lymphotropic virus 1]] | ||
* [[Myelopathy]] | * [[Myelopathy]] | ||
* [[Spasticity]] | |||
==References== | |||
{{Reflist}} | |||
==Images== | |||
[[File:HTLV-1_EM_8241_lores.jpg|thumb|Electron micrograph of HTLV-1]] | |||
[[File:Polymyositis_HE.jpg|thumb|Histopathological image of muscle tissue]] | |||
[[File:Immunoglobulin.png|thumb|Diagram of an immunoglobulin molecule]] | |||
[[Category:Neurological disorders]] | [[Category:Neurological disorders]] | ||
[[Category:Viral diseases]] | [[Category:Viral diseases]] | ||
[[Category: | [[Category:Rare diseases]] | ||
Revision as of 23:58, 9 February 2025
A disease caused by the human T-lymphotropic virus 1
Tropical spastic paraparesis (TSP), also known as HTLV-1 associated myelopathy (HAM), is a progressive neurological disorder caused by the human T-lymphotropic virus 1 (HTLV-1). It primarily affects the spinal cord, leading to muscle weakness, spasticity, and other neurological symptoms.
Signs and symptoms
Tropical spastic paraparesis is characterized by progressive weakness and stiffness of the legs, leading to difficulty walking. Patients may also experience back pain, urinary incontinence, and erectile dysfunction. Sensory disturbances, such as numbness or tingling, can occur, although they are less common.
Causes
TSP is caused by infection with the human T-lymphotropic virus 1 (HTLV-1), a retrovirus that primarily infects T cells. The virus is transmitted through blood, sexual contact, and from mother to child via breastfeeding. Not all individuals infected with HTLV-1 develop TSP; the disease occurs in a small percentage of those infected.
Pathophysiology
The exact mechanism by which HTLV-1 causes TSP is not fully understood. It is believed that the virus triggers an immune response that leads to inflammation and damage to the spinal cord. This results in the characteristic symptoms of the disease.
Diagnosis
Diagnosis of TSP involves clinical evaluation, magnetic resonance imaging (MRI) of the spinal cord, and laboratory tests to detect HTLV-1 antibodies in the blood or cerebrospinal fluid.
Treatment
There is no cure for TSP, and treatment focuses on managing symptoms. Corticosteroids and other immunosuppressive drugs may be used to reduce inflammation. Physical therapy can help maintain mobility and muscle strength.
Prognosis
The progression of TSP varies among individuals. Some patients experience a slow progression of symptoms, while others may have a more rapid decline. Early diagnosis and management can help improve quality of life.
Epidemiology
TSP is most commonly found in regions where HTLV-1 is endemic, such as parts of Japan, the Caribbean, South America, and Africa. The prevalence of the disease is higher in women than in men.
Related pages
References
<references group="" responsive="1"></references>
Images
